An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis

Documenti analoghi

• Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
  di: Si, Tianmei, et al.
  Pubblicazione: (2015)
• Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
  di: Kang, Nam-In, et al.
  Pubblicazione: (2016)
• Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study
  di: Si, Tian Mei, et al.
  Pubblicazione: (2019)
• Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
  di: Yang, Fu De, et al.
  Pubblicazione: (2017)
• Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
  di: Kongsakon, Ronnachai, et al.
  Pubblicazione: (2017)